Advances in immunotherapy of castration-resistant prostate cancer: bisphosphonates, phosphoantigens and more

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• Medical advancements have increased survival for castration-resistant prostate cancer (CRPC) patients.
• Limited effective therapies for CRPC necessitate novel treatment strategies, particularly in immunotherapy.
• Human gammadelta T-cells are a key focus for novel immunotherapeutic approaches.

Purpose of the Study:

• To explore the potential of activating gammadelta T-cells as an innovative immunotherapy for prostate cancer.
• To review existing methods for gammadelta T-cell activation, including phosphoantigens and aminobisphosphonates.
• To discuss the therapeutic implications of in vivo gammadelta T-cell activation in CRPC management.

Main Methods:

• Review of current literature on gammadelta T-cell biology and activation pathways.
• Analysis of endogenous phosphoantigens and exogenous agents like aminobisphosphonates.
• Discussion of the role of interleukin-2 in modulating T-cell responses.

Main Results:

• Gammadelta T-cells can be activated by phosphoantigens and agents like aminobisphosphonates.
• Aminobisphosphonates are clinically established and can induce gammadelta T-cell accumulation.
• Interleukin-2 can potentially enhance gammadelta T-cell activity.

Conclusions:

• Intentional in vivo activation of gammadelta T-cells presents a promising avenue for novel prostate cancer immunotherapy.
• Combining phosphoantigens or aminobisphosphonates with interleukin-2 may offer a synergistic approach.
• This strategy holds potential for developing highly innovative treatments for patients with advanced prostate cancer.